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Abstract
Enteral Nutrition (EN) is recommended as first line nutritional support for patients undergoing Allogeneic
Hematopoietic Stem Cell Transplantation (allo-HSCT), but only few studies exist in the literature which compare EN
to Parenteral Nutrition (PN) in the paediatric population.
Forty-two consecutive paediatric patients undergoing allo-HSCT at our referral centre between January 2016 and
July 2019 were evaluated. Post-transplant and nutritional outcomes of patients receiving EN for more than 7 days
(EN group, n = 14) were compared with those of patients receiving EN for fewer than 7 days or receiving only PN
(PN group, n = 28). In the EN group, a reduced incidence of Blood Stream Infections (BSI) was observed (p = 0.02)
(n = 2 vs. n = 15; 14.3% vs. 53.6%). The type of nutritional support was also the only variable independently associated
with BSI in the multivariate analysis (p = 0.03). Platelet engraftment was shorter in the PN group than in the EN group
for a threshold of > 20*109/L (p = 0.04) (23.1 vs 35.7 days), but this correlation was not confirmed with a threshold of >
50*109/L. The Body Mass Index (BMI) and the BMI Z-score were no different in the two groups from admission to
discharge.
Our results highlight that EN is a feasible and nutritionally adequate method of nutritional support for children
undergoing allo-HSCT in line with the present literature. Future functional studies are needed to better address the
hypothesis that greater intestinal eubyosis maintained with EN may explain the observed reduction in BSI.
Keywords: Enteral nutrition, Parenteral nutrition, Hematopoietic stem cell transplantation, Paediatrics, Blood stream
infections, Gut microbiota
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Introduction
Allogeneic Hematopoietic Stem Cell Transplantation
(allo-HSCT) is a potentially curative strategy for many
oncological, haematological, metabolic and immuno-
logical diseases in children. It includes a conditioning
regimen with chemotherapy, radiotherapy and immuno-
therapy, allowing patients to receive donor haematopoi-
etic stem cells [1, 2]. Despite the recent advances in the
field, the procedure is still associated with marked mor-
bidity and mortality [3], mainly due to recurrence of the
primary disease or to transplant-related complications.
The two leading complications are infections, particu-
larly bacterial blood stream infections (BSI), and acute
Graft versus Host Disease (aGvHD) [2, 3]. The latter is
characterised by the response of alloreactive donor T
cells to host organs including the skin, gut and liver [4]
while infections are favoured by prolonged immunosup-
pression and mucosal damage [2].
The majority of children start treatment in a relatively
healthy nutritional status [5]. Oral feeding in the early
post-transplant period is impaired because of conditioning
regimen-side effects, mainly vomiting, anorexia, diarrhoea
and mucositis. The reduction in caloric intake gives rise to
a rapid deterioration of the nutritional status [5–7] which
is associated with lower overall survival as well as higher
complication rates during treatment [8–10].
Historically, parenteral nutrition (PN) was considered to
be the method of choice for the nutritional support of pa-
tients undergoing allo-HSCT [11]. However, in light of
PN-related complications (sepsis, metabolic and hepatic
disorders, gut mucosal atrophy) [12], some concerns have
been raised regarding its use [13–16]. Another feeding op-
tion is Enteral Nutrition (EN) which involves the adminis-
tration of nutrients directly into the digestive system via a
nasogastric tube (NGT), and has been shown to be feas-
ible and effective in other clinical settings [17–19]. Cur-
rently, the international guidelines provided by European
Bone Marrow Transplantation and ESPEN recommend
EN as first line nutritional support for patients undergoing
allo-HSCT [20, 21]. Nevertheless, a recent survey has
shown that the majority of European transplant centres
still use PN over EN, mainly due to the constant availabil-
ity of central venous access [22]. Another possible explan-
ation is the preference given to PN by caregivers because
of the perceived invasiveness of EN [23].
In the paediatric population, the few studies compar-
ing EN to PN involving a limited number of patients,
found that EN had potential benefits regarding aGvHD
and platelet engrafment [24]. Considering the increasing
knowledge concerning the role of gut microbiota dysbio-
sis in the development of main complications after
HSCT, these benefits may be potentially explained by
the maintenance of gut eubyosis and epithelium integrity
in patients receiving EN [25].
Thus, the aim of this study was to evaluate the role of
EN regarding clinical and nutritional outcomes in paedi-
atric allo-HSCT recipients and to comprehend the im-




Consecutive patients undergoing allo-HSCT for either
malignant or non-malignant disease were evaluated at
the Paediatric HSCT Unit of Sant’Orsola Hospital in
Bologna, Italy, between January 2016 and July 2019. The
study protocol was approved by the University of Bol-
ogna Ethics Committee (ref. number 19/2013/U/Tess).
Written informed consent authorising the medical re-
cords to be used for research purposes was obtained
from each enrolled patient or parent/legal guardian be-
fore data collection in accordance with the Declaration
of Helsinki.
Transplantation procedure
Conditioning regimen and aGvHD prophylaxis were
adopted according to national and international guide-
lines, based on patient age, comorbidities, disease, donor
and stem cell source. Conditioning regimens were di-
vided into Myeloablative conditioning (MAC) or non-
Myeloablative conditioning (no-MAC) based on the in-
tensity level of the myeloablation provided [3].
Granulocyte-Colony Stimulating Factor (G-CSF) was ad-
ministered according to the patient’s disease and haem-
atological status.
The patients were treated in high efficiency particulate
air filtered rooms in order to prevent infections. Anti-
biotic prophylaxis (ABP) or gut decontamination were
not used for any patient.
The presence or absence of cytomegalovirus and
Epstein-Barr virus were checked in both donor and
recipient.
In the case of febrile neutropenia, patients were
treated using empiric broad-spectrum intravenous anti-
biotics, with ceftazidime as the first choice, after obtain-
ing blood cultures from a peripheral and a central line.
Nutritional support during the neutropenic period
In allo-HSCT performed before 2018, only PN was uti-
lised while, starting from January 2018, EN was pro-
posed as the first choice of nutritional support during
the neutropenic period. Parenteral nutrition was started
as soon as the patient could not eat properly by mouth
with a hospital-made compound administered by means
of a Central Venous Catheter (CVC). The compound
used did not have a standardised composition, but the
hospital pharmacy regularly provided a customised for-
mula based on the prescription of the physician for each
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patient. Nutritional needs were calculated based on the
weight of the children. The parenteral energy goal was
reached progressively within 2–4 days. The concentration
of glucose given varied from 5.0% to 12.5%. Calories de-
rived from glucose represented 70% of the non-proteic
calories. The remaining 30% were derived from lipids
given in the form of soybean oil emulsion. Proteins were
given at a dose of 1 g/kg/day. Oligoelements, vitamins and
electrolytes were also administered as supplements.
The EN was administered via a nasogastric tube (NGT)
using a commercial formula. Information regarding the
enteral mixture administered is reported in Supplemen-
tary Table S1. The families received appropriate informa-
tion regarding EN and NGT positioning during a pre-
transplantation interview. Depending on the child’s age,
the patient also received information. The NGT was
inserted between days − 2 and + 2 from HSCT. The caloric
goal was based on the basal metabolism rate, calculated
according to the Schofield formula [26, 27]. To improve
tolerability, the starting dose was lower than the calculated
goal, and scaled up in the following days depending on pa-
tient tolerance. The EN was administered either continu-
ously, with a break during the night, or by bolus.
Patients who did not tolerate EN due to vomiting, nau-
sea, diarrhoea, abdominal discomfort, gastric residuals or
NGT intolerance were switched to PN. In the case that an
inadequate amount of calories were delivered with EN,
supplementation with an intravenous glucose solution or
PN was administered. The EN and PN were stopped as
soon as the patient was able to eat on his/her own.
Study design, transplantation and nutritional outcomes
Children receiving EN for more than 7 days were in-
cluded in the EN group while children receiving EN for
fewer than 7 days or receiving only PN were included in
the PN group (Fig. 1). Patients who received a second
allo-HSCT and/or those having previous chronic bowel
disease were excluded from this study.
In order to assess the effect of the route of nutritional
support on clinical and nutritional outcomes, certain
data were recorded from admission to discharge. Neu-
trophil and platelet engraftments were defined as 3 con-
secutive days with a count > 0.5 *109/L and 7
consecutive days transfusion free with a count > 20*109/
L or > 50*109/L, respectively. Oral mucositis occurrence
was evaluated by a nurse and a physician, and graded ac-
cording to the World Health Organization (WHO) cri-
teria [28]. Acute graft versus host disease was diagnosed
on the basis of clinical symptoms and graded from 0 to
IV according to the Glucksberg classification [29]. Ster-
oid resistant gut aGvHD was defined as progression
within 3–5 days of starting corticosteroid treatment or
an incomplete response by 7–14 days [21].
Veno-occlusive disease was diagnosed according to the
recent paediatric criteria proposed by the European So-
ciety for Blood and Marrow Transplantation [30]. Blood
stream infections (BSI) were considered only when con-
firmed by a positive bacterial blood culture. The dur-
ation of fever and antibiotic therapy was evaluated only
in the first 30 days, based on the theory that, in this time
span, infections were mainly caused by the patient’s
Fig. 1 Flowchart of subject recruitment and nutritional support modalities. Abbreviations: EN = Enteral Nutrition; n = number of patients;
PN = Parenteral Nutrition
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endogenous bacterial flora [21]. Transplant-related mor-
tality was assessed on day 100 after transplantation.
Body weight was recorded at admission, once a week
from the day of the HSCT to day + 35 and at discharge
in order to evaluate the effect of the nutritional support.
Maximum weight loss was calculated by subtracting the
lowest weight recorded during hospitalisation from the
baseline value (considered that of the day of HSCT).
Weight loss > 10% of the baseline value was then consid-
ered for the analysis.
The Body Mass Index (BMI) was then calculated
using the following formula: BMI=Weight (kg)/ Height2
(cm). The height considered for the calculation was
that recorded at admission. The BMI Z-score was cal-
culated for children from 2 to 20 years of age using the
online calculator of “The Children Hospital of Philadel-
phia” [31], based on Centers for Disease Control and
Prevention growth charts [32]. For patients under 2
years of age, the Z-score was obtained using WHO
growth charts [33]. Albumin supplements, hypopho-
sphatemia (< 2.5 mg/dl) and the elevation of gamma-
glutamyltransferase (> 24 U/L) and direct bilirubin (>
0.30 mg/dl) were reported in order to investigate poten-
tial adverse effects of PN.
Statistical analysis
Qualitative variables were compared using Fisher’s exact
test while means were compared using the t-test corrected
in case of unequal variances. Only p values < 0.05 were
considered to be statistically significant. Transplant-
related mortality (TRM) Kaplan-Meier curves were com-
pared with log-rank test while cumulative incidence of BSI
and aGvHD was calculated using the Kalbfleisch and
Prentice method and was compared using the Gray test.
In order to investigate the variables associated with
the incidence of BSI, univariate and multivariate analyses
were carried out using logistic regression, entering only
variables considered statistically significant (p < 0.05) in
the univariate analysis into the multivariate analysis.
Results
Forty-two patients were enrolled, 14 and 28 in the EN
and PN groups, respectively. Enteral nutrition was pro-
posed for 22 patients of whom 64% (n = 14/22) received
it for more then 7 days.
The two groups were homogeneous as no statistically
significant differences were found regarding age, gender,
diagnosis (malignant/non-malignant), disease status at
transplant (remission/no remission), donor (Matched
Table 1 Patient characteristics at admission and transplantation modalities by group
EN group (n = 14) PN group (n = 28) p
Age: months, mean (range) 131.2 (4.1–251.4) 132.4 (10.3–213.1) NS
Sex: M/F, n, 4/10 16/12 NS
Diagnosis of Malignant Disease, n,(%) 12 (85.7) 23 (82.1) NS
CR at transplant for malignant disease,n, (%) 8 (61.5) 17 (70.8) NS
Donor, n, (%): NS
• Sibling HLA identical 1 (7.2) 5 (17.9)
• MUD 7 (50) 19 (67.8)
• MMUD 3 (21.4) 1 (3.6)
• Haploidentical 3 (21.4) 3 (10.7)
Stem cell source, n, (%): NS
• BM 12 (85.8) 26 (92.9)
• PBSC 1 (7.1) 2 (7.1)
• CB 1 (7.1) 0 (0)
Sex Mismatch, n, (%) 7 (50) 15 (53.6) NS
Infused stem cell dose, median (x108 MNC/kg) 4.71 4.66 NS
Conditioning regimens, n, (%):
• MAC 13 (92.9) 23 (82.1) NS
• With ATG 10 (71.4) 20 (71.4) NS
BMI, mean 17.56 18.76 NS
BMI Z-score, mean −0.37 −0.06 NS
Abbreviations: EN= Enteral Nutrition, PN= Parenteral Nutrition NS= Not statistically Significant, CR= Complete Remission, HLA= Human Leucocyte Antigen, MUD=
Matched Unrelated Donor, MMUD= Mismatched Unrelated Donor, BM = Bone Marrow, PBSC= Peripheral Blood Stem Cell, CB= Cord Blood, MNC= Mononuclear
Cells, MAC= Myeloablative Condioting, ATG= Anti-Thymocite Globulin, BMI= Body Mass Index
Statistical analysis used to calculate the p value: qualitative variables were compared using Fisher’s exact test, while means were compared with t-test corrected in case
of unequal variances. p < 0.05 were considered statistically significant
Zama et al. Nutrition Journal           (2020) 19:29 Page 4 of 9
Familial, Matched Unrelated, Mismatched Unrelated,
haploidentical), infused stem cell dose, source of stem
cells (bone marrow, peripheral blood, cord blood), sex-
matching between the donor and the recipient, condi-
tioning regimen (MAC/no MAC), GvHD prophylaxis.
The BMI and the Z score before transplantation were
also comparable in the two groups (Table 1).
Although no statistically significant difference was
found regarding nutritional outcomes, some noteworthy
dissimilarities were observed in the two groups. The dur-
ation of the nutritional support was shorter in the EN
group (p = 0.09) (Median: 20.7 vs. 30.7 days; Range: 12–28
vs. 10–156). Earlier oral realimentation was also observed
in the EN group (p = 0.08) (20.9 vs. 27 days) (Table 2). The
BMI and the BMI Z-score during hospitalisation were not
statistically significantly different between the two groups,
but there was a greater reduction in the BMI and the BMI
Z-score in the PN group after oral realimentation (Fig. 2).
Table 2 Post-transplant outcome relative to nutritional support
EN group (n = 14) PN group (n = 28) p
Engrafment:
Neutrophil, days, mean 17.31 16.86 0.78
PLT > 20*109, days, mean 35.67 23.14 0.04
PLT > 50*109, days, mean 36.40 30,89 0.45
Duration of G-CSF, days, mean 11.62 10.46 0.51
Oral mucositis:
Grade 3–4, n, (%) 5 (35.7) 3 (10.7) 0.10
Duration, days, mean 13.46 13.54 0.98
aGvHD:
Grade I-IV, n, (%) 6 (42.9) 13 (46.4) 1.00
Grade III-IV, n, (%) 1 (16.7) 5 (38.46) 0.52
Gut aGvHD, n, (%) 4 (28.6) 8 (28.6) 1.00
Gut aGvHD +++/++++, n, (%) 0 (0) 5 (17.9) 0.08
Steroid Resistant Gut aGvHD, n, (%) 0 (0) 6 (21.4) 0.06
Infections:
BSI, n, (%) 2 (14.3) 15 (53.6) 0.02
Duration of fever in the first 30 days post HSCT, days, mean 8.00 11.21 0.07
Length of Antibiotic therapy in the first 30 days post HSCT, days, mean 18.54 19.38 0.65
VOD, n, (%) 2 (14.3) 5 (17.9) 1.00
Length of hospital stay, days, mean 71.8 60.1 0.28
Transfer to ICU, n, (%) 2 (14.3) 3 (10.7) 1.00
Nutritional Support:
Length of nutritional support, days, mean 20.71 30.71 0.09
Start of oral realimentation, days, mean 20.85 26.96 0.08
Nutritional Parameters
Lowest weight, Kg, mean 29.78 36.63 0.31
Maximum weight loss %, mean 11.5 9.9 0.44
Weight loss > 10%, n, (%) 7 (50) 9 (32.2) 0.30
Metabolic Parameters:
Albumin transfusions, U, mean 6,31 13.79 0.14
Hypophosphatemia, n, (%) 8 (57,1) 21 (75) 0.10
γGT and/or direct bilirubin elevation, n, (%) 11 (78,6) 24 (85.7) 0.26
Abbreviations: EN= Enteral Nutrition, PN= Parenteral Nutrition, PLT= Platelets, G-CSF= Granulocyte-Colony Stimulating Factor, aGvHD= Acute Graft versus Host
Disease, BSI= Blood Stream Infections, HSCT= Hematopoietic Stem Cell Transplantation, VOD= Veno Occlusive Disease, ICU= Intensive Care Unit,
γGT= Gamma.glutamyltransferase
Statistical analysis used to calculate the P value: qualitative variables were compared using Fisher’s exact test, while means were compared with t-test corrected in case
of unequal variances. p < 0.05 were considered statistically significant and underlined in the table
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Fig. 2 Mean BMI during hospitalisation in the EN and PN groups. There was no statistically significant difference in BMI and BMI Z-score at any
time point between the EN group and the PN group from admission to discharge. The timing of start of the oral realimentation is highlighted in
the figure. Abbreviations: BMI = Body Mass Index; EN = Enteral Nutrition; HSCT = Haematopoietic Stem Cell Transplantation; PN = Parenteral Nutrition
Fig. 3 Cumulative Incidence of BSI in the EN and PN groups. Cumulative incidence was calculated using the Kalbfleisch and Prentice method
and compared using the Gray test. Abbreviations: BSI = Blood Stream Infection; E = number of Events; EN = Enteral Nutrition; HSCT = Haematopoietic
Stem Cell Transplantation; N = Number of patients; PN = Parenteral Nutrition
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In the EN group, a reduced incidence of BSI was ob-
served (p = 0.02) (n = 2 vs. n = 15; 14.3% vs. 53.6%). This
was also confirmed by the analysis of cumulative inci-
dence of BSI (p = 0.02) (Fig. 3). The following variables
were tested in the univariate analysis to better investi-
gate their association with the incidence of BSI: age,
diagnosis (malignant/non-malignant), disease status at
transplant (remission/no remission), donor (Matched Fa-
milial, Matched Unrelated, Mismatched Unrelated, hap-
loidentical), infused stem cell dose, source of stem cells
(bone marrow, peripheral blood, cord blood), sex-
matching, conditioning regimen (MAC/no MAC),
aGvHD prophylaxis, nutritional group (EN group vs. PN
group), duration of nutritional support, maximum
weight loss, number of albumin transfusions, neutrophil
engraftment, days of G-CSF administration, incidence
and grading of aGvHD, incidence and duration of muco-
sitis and length of hospital stay.
The incidence of BSI was only significantly affected by
the type of conditioning regimen (MAC/no MAC) (p =
0.04) and the nutritional group (EN group vs. PN group)
(p = 0.02). Notably, the multivariate regression model
confirmed the type of nutritional support (EN group vs.
PN group) (p = 0.03) as the only variable independently
associated with BSI.
A shorter duration of fever in the first 30 days post-
transplant was also observed in the EN group, even
though not statistically significant. (p = 0.07) (8 vs.11.2
days). No difference was found in the length of antibiotic
therapy during the same time span (p = 0.65) (18.5 vs.
19.4). (Table 2).
Time to neutrophil engraftment and days of G-CSF
administration were not different between the groups. A
longer time to platelet recovery > 20*109/L was observed
in the EN group (p = 0.04) (35.7 vs. 23.1 days) but the
correlation was not confirmed considering time to plate-
let recovery > 50*109/L.
No difference was found regarding the occurrence of
aGvHD between the two groups, although a trend in the
EN group was observed for reduced incidence of severe
gut aGvHD (Grade III-IV) (p = 0.08) and steroid-
resistant gut aGvHD (p = 0.06).
No difference was found in terms of grade 3–4 and
duration of mucositis, incidence of veno-occlusive dis-
ease, transfer to the intensive care unit, length of hos-
pital stay and TRM.
Discussion
The present study showed that EN was a feasible and
nutritionally adequate method of nutritional support,
with adherence to treatment comparable to other paedi-
atric experiences reported in the literature [13, 34, 35].
No statistically significant difference was observed be-
tween the two groups regarding BMI, BMI Z-score and
weight loss during hospitalisation, supporting the idea
that EN may at least be comparable to PN in terms of
nutritional support. Currently, there is no consensus re-
garding which parameter best determines malnutrition
in children undergoing allo-HSCT. Body weight and
BMI are easily applicable in clinical practice, but lack in-
formation on body composition and are heavily influ-
enced by hydro-electrolytic imbalance occurring during
the procedure, thus not directly reflecting the patient’s
nutritional status [5, 6, 36, 37]. Additional studies com-
paring laboratory parameters, such as retinol-binding
protein, or more detailed anthropometric measures, for
example triceps skin fold thickness, are needed to better
understand the influence of the type of nutritional sup-
port on overall patient nutritional status.
This paper is the first to cite evidence regarding the
paediatric population that EN may protect from BSI in
allo-HSCT patients not receiving ABP. The rate of BSI
in the PN group was superimposable to that reported in
other cohorts [13, 38]. The Authors speculated that the
reduction in BSI not observed in other experiences could
be due to the use of ABP potentially overlapping the
protective role of EN.
Central venous catheter-related infections and the
translocation of bacteria from the endogenous intestinal
flora to the bloodstream represent the two main sources
of bacterial infections in HSCT recipients [21]. Central
venous catheter-related infectious risk may be reduced
in the EN group due to the reduced use of PN, with a
lower frequency in CVC handling [12]. Furthermore, PN
may induce gut mucosal atrophy and greater dysbiosis
[25, 39], thus promoting bacterial translocation through
the intestinal mucosal barrier, and increasing the risk of
intestinal bacterial domination by pathogens connected
to BSI [40]. The protective role of EN from BSI could be
associated with the trophic effect on the gut epithelium,
either directly due to a greater presence of nutrients in
loco, or indirectly via the production of short chain fatty
acids from the gut microbiota [41, 42]. Another possible
mechanism involved in the reduction of bacterial trans-
location is the maintenance of a thicker mucin layer in
enterally fed patients [43].
The other main experiences comparing EN to PN re-
ported in the literature showed a reduced incidence of
aGvHD and, in particular, gut aGVHD [13, 38] which
may also be linked to the potential reduction in dysbiosis
in patients receiving EN. The data in the present study
regarding gut aGvHD was in line with the results men-
tioned above, but failed to reach statistical significance.
A larger sample size may be needed to point out the
possible effect of EN on aGvHD .
The hypothesis that EN maintained a greater intestinal
eubyosis after allo-HSCT has been confirmed by two re-
cent studies. The first by Andersen et al. involved adult
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patients receiving ABP; it found no difference in micro-
bial diversity, but a greater abundance of taxa associated
with the increased production of short chain fatty acids,
such as Faecalibacterium, in patients who predominantly
received EN [44]. D’Amico et al. analysed longitudinally
the trajectory of the compositional and functional recov-
ery of gut microbiota in twenty paediatric patients
undergoing HSCT from the same cohort in this study, of
which ten were fed post-transplant with EN and ten with
total PN. They observed the prompt recovery of a struc-
tural and functional eubiotic gut microbiota and short
chain fatty acid layout after the disruption induced by
the allo-HSCT procedure only in EN patients [45].
These results seemed to support the hypothesis that the
reduced incidence of BSI observed in this study may also
be explained by the eubiotic effect that EN has on the
gut microbiome, promoting homeostasis of the intestinal
ecosystem.
In this regard, it has not been established what role
the duration of nutritional support with EN played on
protecting the endogenous flora. To date, no study
exists in the literature evaluating how long EN should
be administered with the aim of inducing a protective
effect on the microbiome. Therefore, the Authors ar-
bitrarily decided to consider a duration of EN lasting
for good part of the neutropenic phase after trans-
plantation. However, additional studies are needed to
address the significant variables connected to EN,
namely duration, composition of the formula and cal-
oric content.
Conclusions
The results in the present study showed a potentially
beneficial role of EN as the first choice of nutritional
support in children undergoing allo-HSCT, with a re-
duction in the incidence of BSI. Given the perceived in-
vasiveness of the method and its challenges, EN should
be implemented by a motivated and committed multi-
disciplinary team, composed of paediatric haematolo-
gists, gastroenterologists, nurses and dieticians.
Additional studies involving a larger number of pa-
tients are needed in the specific paediatric allo-HSCT
setting to confirm the potential benefits of EN over PN.
In this regard, it is hoped that a multicentre randomised
controlled study could be arranged in the near future in-
volving a paediatric population, mirroring the one cur-
rently ongoing in adult patients [46], in order to give
further evidence supporting the use of EN in paediatric
allo-HSCT recipients. Additional functional gut micro-
biota analyses are also needed to better address the hy-
pothesis that a maintained greater intestinal eubyosis
may explain the observed reduction in BSI, or aGvHD,
in transplanted children receiving EN.
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